Research programme: stem cell therapy - Rohto Pharmaceutical

Drug Profile

Research programme: stem cell therapy - Rohto Pharmaceutical

Latest Information Update: 12 Apr 2014

Price : $50

At a glance

  • Originator Rohto Pharmaceutical
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 25 Mar 2014 Early research in undefined indication in Japan (unspecified route)
  • 25 Mar 2014 Rohto Pharmaceutical enters into an R&D agreement with BioRestorative Therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top